We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Stock futures edged higher on Friday, following an eventful week marked by strong bank earnings and a slew of mixed economic data. Here are some of Friday's biggest stock movers: Biggest stock gainers ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...

ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

The acquisition's total consideration is $200 million in cash and Symbotic will pay Walmartup to $350 million in additional contingent consideration in future periods dependent upon the quantity of ...

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

In November 2024, the JP Conte Family Foundation made a transformative $5 million gift to UCSF to establish two professorships in the Department of Neurology. These endowed positions, overseen by ...